The association of renin–angiotensin system blockades and pneumonia requiring admission in patients with COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2159-2166

  Kim, Junghyun ^a   Lee, Jung Kyu ^b   Heo, Eun Young ^b   Chung, Hee Soon ^b   Kim, Deog Kyeom ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitors; COPD; Pneumonia

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PNEUMONIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SOUTH KOREA; TREATMENT DURATION; UNIVERSITY HOSPITAL;

EID: 84988815036     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S104097     Document Type: Article

References (47)

1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1): 188–207.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 2014. Available from: http://www.goldcopd.org. Accessed January 1, 2015.
3. Afonso AS, Verhamme KM, Sturkenboom MC, Brusselle GG. COPD in the general population: prevalence, incidence and survival. Respir Med. 2011;105(12):1872–1884.
4. Maureen PMH, van-Mölken R, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease. Pharmacoeconomics. 2001; 19(2):1–6.
5. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750.
6. Chao J, Donham P, van Rooijen N, Wood JG, Gonzalez NC. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia. Am J Respir Cell Mol Biol. 2011;45(1):53–61.
7. Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res. 2010;33(1): 11–21.
8. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des. 2003;9:715–722.
9. Oarhe CI, Dang V, Dang M, et al. Hyperoxia downregulates angiotensinconverting enzyme-2 in human fetal lung fibroblasts. Pediatr Res. 2015; 77(5):656–662.
10. Şahan AG, Yılmaz A, Taşlıyurt T, et al. Antiinflammatory effect of telmisartan on chronic obstructive pulmonary disease: 8-isoprostane concentration in exhaled breath condensate. Cumhuriyet Med J. 2014; 36(2):178–183.
11. Young RP, Hopkins RJ. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev Respir Med. 2013;7(5):533–544.
12. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008; 31(6):1334–1356.
13. Hussain S, Algaem M, Numan I. Anti-inflammatory effects of Telmisartan and Valsartan in animal models of airways inflammation. Pharmacologia. 2014;5(4):149–154.
14. Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217.
15. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci. 2012;123(8):487–498.
16. Lang YD, Hung CL, Wu TY, Wang LF, Chen CM. The reninangiotensin system mediates hyperoxia-induced collagen production in human lung fibroblasts. Free Radic Biol Med. 2010;49(1):88–95.
17. Podowski M, Calvi C, Metzger S, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229–240.
18. Katsumata U, Sekizawa K, Ujie Y, Sasaki H, Takishima T. Bradykinininduced cough reflex markedly increases in patients with cough associated with captopril and enalapril. Tohoku J Exp Med. 1991;164:103–109.
19. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet. 1998;352(9133):1069.
20. Raiden S, Nahmod K, Nahmod V, et al. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Ther. 2002;303(1):45–51.
21. Wang HC, Lin CC, Lau CI, Chang A, Kao CH. Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease. Mov Disord. 2015;30(4):593–596.
22. Shah S, McArthur E, Farag A, et al. Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study. PLoS One. 2014;9(10):e110165.
23. Shinohara Y, Origasa H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther. 2012;29(10):900–912.
24. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55(11):1466–1473.
25. Liu CL, Shau WY, Wu CS, Lai MS. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens. 2012;30(11):2223–2229.
26. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260.
27. Liu C-L, Shau W-Y, Chang C-H, Wu C-S, Lai M-S. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. J Epidemiol. 2013;23(5):344–350.
28. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31(3): 611–617.
29. Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ. 2012;184(7):E367–E372.
30. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratoryconfirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205(1):13–19.
31. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2014. Available from: http://ginaasthma.org. Accessed January 1, 2015.
32. Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P. Canadian asthma consensus report, 1999. CMAJ. 1999;161(11):S1–S61.
33. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
34. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulm Dis. 2013;8:295–304.
35. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11): 1029–1036.
36. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulm Dis. 2009;4:203–223.
37. Johnson D, Coley S. Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension. Lancet. 1998; 352(9133):1069–1070.
38. Crisafulli E, Menendez R, Huerta A, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013;143(4):1009–1017.
39. Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506–3515.
40. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7): 247–257.
41. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28(1):219–242.
42. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181–190.
43. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in nonsmokers. Lancet. 2009;374:733–743.
44. Vegter S, Nguyen NH, Visser ST, Lolkje TW, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609–616.
45. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6(3):271–276.
46. Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133.
47. Marta V, Olga L, Sandra M, et al. Medication adherence to specific drug classes in chronic heart failure. J Manag Care Pharm. 2014;20(10): 1018–1026.